Equities Analysts Set Expectations for CTXR FY2026 Earnings

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Equities research analysts at HC Wainwright lowered their FY2026 EPS estimates for Citius Pharmaceuticals in a research note issued to investors on Wednesday, August 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($2.03) for the year, down from their previous forecast of ($1.87). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.31) EPS and FY2027 earnings at ($1.44) EPS.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $5.46 million.

Several other research firms have also recently weighed in on CTXR. Citigroup reiterated a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday. Wall Street Zen downgraded shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Zacks Research raised shares of Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Citius Pharmaceuticals has a consensus rating of “Hold” and an average target price of $5.00.

Citius Pharmaceuticals Stock Performance

NASDAQ:CTXR opened at $0.60 on Friday. The stock has a 50 day simple moving average of $0.59 and a 200 day simple moving average of $0.69. The stock has a market cap of $16.47 million, a P/E ratio of -0.36 and a beta of 1.03. Citius Pharmaceuticals has a 1-year low of $0.47 and a 1-year high of $2.19. The company has a current ratio of 0.84, a quick ratio of 0.16 and a debt-to-equity ratio of 0.08.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in Citius Pharmaceuticals during the second quarter worth $32,000. NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at $40,000. Asset Advisory Group Inc. bought a new position in shares of Citius Pharmaceuticals in the 4th quarter valued at $46,000. Heights Capital Management Inc. acquired a new position in shares of Citius Pharmaceuticals during the 4th quarter worth $622,000. Finally, BlackRock Inc. acquired a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth $42,000. 16.88% of the stock is owned by institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.